Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
伊利諾伊州鹿園，2024年4月29日（GLOBE NEWSWIRE）——專注於開發和商業化罕見疾病療法的創新制藥公司伊頓製藥公司（“伊頓” 或 “公司”）（納斯達克股票代碼：ETON）今天宣佈，將於2024年5月9日星期四公佈2024年第一季度財務業績。管理層將在美國東部時間下午 4:30（美國東部時間下午 3:30）主持電話會議和網絡直播，討論結果。
| Register* (Audio Only) | Click Here |
| 註冊*（僅限音頻） | 點擊這裏 |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the Investors section of Eton's website at https://ir.etonpharma.com/. An archived webcast will be available on Eton's website approximately two hours after the completion of the event and for 30 days thereafter.
除了在電話會議上回答參與者的現場提問外，管理層還將回答投資者通過電子郵件發送的問題。投資者可以通過電子郵件將問題發送至： investorrelations@etonpharma.com。
可以在伊頓公學網站的 “投資者” 部分觀看網絡直播，網址爲 https://ir.etonpharma.com/。存檔的網絡直播將在活動結束大約兩小時後在伊頓公學的網站上提供，之後將持續30天。
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
*電話會議參與者應註冊以獲取其撥入和密碼的詳細信息。請務必使用有效的電子郵件地址註冊。
About Eton Pharmaceuticals
關於伊頓製藥
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
伊頓是一家創新制藥公司，專注於開發和商業化罕見疾病的治療方法。該公司目前有五種商用罕見病產品：ALKINDI SPRINKLE、PKU GOLIKE、Carglumic Acid、無水甜菜鹼和尼替西農。該公司還有另外三種候選產品處於後期開發階段：ET-400、ET-600 和ZENEO氫化可的松自動注射器。欲了解更多信息，請訪問我們的網站 www.etonpharma.com。
Investor Relations:
投資者關係：
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
麗莎·威爾遜
In-Site Communications
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals
來源：伊頓製藥
Source: Eton Pharmaceuticals
來源：伊頓製藥
譯文內容由第三人軟體翻譯。